बिड संख्या/Bid Number: GEM/2026/B/8127320

दिनांक /Dated: 05-11-2026

बिड दस्तावेज़ / Bid Document

बिड विवरण/Bid Details	
बिड बंद होने की तारीख/समय /Bid End Date/Time	16-11-2026 10:00:00
बिड खुलने की तारीख/समय /Bid Opening Date/Time	17-11-2026 10:00:00
बिड पेशकश वैधता (बंद होने की तारीख से)/Bid Offer Validity (From End Date)	180 (Days)
मंत्रालय/राज्य का नाम/Ministry/State Name	Andaman & Nicobar
विभाग का नाम/Department Name	Health Department Andaman & Nicobar
संगठन का नाम/Organisation Name	N/a
कार्यालय का नाम/Office Name	Directorate Of Health Services
शिकायत निवारण के संपर्क विवरण/ Contact details of Grievance redressal	HOD Email id :noitdhs@nic.in Buyer Email id: manoj.d1979@and.nic.in
कुल मात्रा/Total Quantity	136300
वस्तु श्रेणी /Item Category	Noradrenaline Injection (Q2) , Adrenaline Injection (V2) (Q2) , Lignocaine Injection (Q2) , Isoflurane Liquid for Inhalation (Q2) , Dexamethasone Injection (Q2) , Dobutamine Injection (Q2) , Fentanyl Injection (Q2) , Hyoscine Butyl Bromide Injection (Q2) , Levetiracetam Injection (Q2) , Morphine Injection (Q2) , Phenytoin Injection (Q2) , Adenosine Injection (V2) (Q2) , Amiodarone Injection (V2) (Q2) , Atracurium Injection (V2) (Q2) , Betamethasone Injection (V2) (Q2) , Erythropoietin Injection (Q2)
पिछले 3 वित्तीय वर्षों का बिडर का न्यूनतम औसत वार्षिक वित्तीय टर्नओवर/Minimum Average Annual Turnover of the bidder (For the last 3 Financial Years)	31 Lakh (s)
मूल उपकरण निर्माता का औसत टर्नओवर (गत 3 वर्षों का)/OEM Average Turnover (Last 3 Years)	47 Lakh (s)
उन्हीं/समान सेवा के लिए अपेक्षित विगत अनुभव के वर्ष/Years of Past Experience Required for same/similar service	2 Year (s)
टर्नओवर पात्रता मानदंड/Turnover eligibility criteria	To be verified by the buyer at the time of technical evaluation
वर्षों के अनुभव एवं टर्नओवर से एमएसई को छूट प्राप्त है / MSE Relaxation for Years Of Experience and Turnover	Yes | Complete

बिड विवरण/Bid Details	
स्टार्टअप के लिए अनुभव के वर्षों और टर्नओवर से छूट प्रदान की गई है / **Startup Relaxation for Years Of Experience and Turnover**	Yes | Complete
विक्रेता से मांगे गए दस्तावेज़/**Document required from seller**	Experience Criteria,Bidder Turnover,Certificate (Requested in ATC),OEM Authorization Certificate,OEM Annual Turnover *In case any bidder is seeking exemption from Experience / Turnover Criteria, the supporting documents to prove his eligibility for exemption must be uploaded for evaluation by the buyer
क्या आप निविदाकारों द्वारा अपलोड किए गए दस्तावेज़ों को निविदा में भाग लेने वाले सभी निविदाकारों को दिखाना चाहते हैं? संदर्भ मेनू है/**Do you want to show documents uploaded by bidders to all bidders participated in bid?**	Yes (Documents submitted as part of a clarification or representation during the tender/bid process will also be displayed to other participated bidders after log in)
बिड लगाने की समय सीमा स्वतः नहीं बढ़ाने के लिए आवश्यक बिड की संख्या। / **Minimum number of bids required to disable automatic bid extension**	2
दिनों की संख्या, जिनके लिए बिड लगाने की समय-सीमा बढ़ाई जाएगी। / **Number of days for which Bid would be auto-extended**	7
ऑटो एक्सटेंशन अधिकतम कितनी बार किया जाना है। / **Number of Auto Extension count**	1
बिड से रिवर्स नीलामी सक्रिय किया/**Bid to RA enabled**	Yes
रिवर्स नीलामी योग्यता नियम/**RA Qualification Rule**	H1-Highest Priced Bid Elimination
बिड का प्रकार/**Type of Bid**	Two Packet Bid
प्राथमिक उत्पाद श्रेणी/**Primary product category**	Erythropoietin Injection
तकनीकी मूल्यांकन के दौरान तकनीकी स्पष्टीकरण हेतु अनुमत समय /**Time allowed for Technical Clarifications during technical evaluation**	2 Days
निरीक्षण आवश्यक (सूचीबद्ध निरीक्षण प्राधिकरण /जेम के साथ पूर्व पंजीकृत एजेंसियों द्वारा)/**Inspection Required (By Empanelled Inspection Authority / Agencies pre-registered with GeM)**	No
Payment Timelines	Payments shall be made to the Seller within **45** days of issue of consignee receipt-cum-acceptance certificate (CRAC) and on-line submission of bills (This is in supersession of 10 days time as provided in clause 12 of GeM GTC)
मूल्यांकन पद्धति/**Evaluation Method**	Item wise evaluation
मध्यस्थता खंड/**Arbitration Clause**	No
सुलह खंड/**Mediation Clause**	No

ईएमडी विवरण/**EMD Detail**

एडवाईजरी बैंक/Advisory Bank	State Bank of India
Schedule 1 ईएमडी राशि/EMD Amount (In INR)	1900
Schedule 2 ईएमडी राशि/EMD Amount (In INR)	1918
Schedule 3 ईएमडी राशि/EMD Amount (In INR)	2100
Schedule 4 ईएमडी राशि/EMD Amount (In INR)	3465
Schedule 5 ईएमडी राशि/EMD Amount (In INR)	7140
Schedule 6 ईएमडी राशि/EMD Amount (In INR)	920
Schedule 7 ईएमडी राशि/EMD Amount (In INR)	2520
Schedule 8 ईएमडी राशि/EMD Amount (In INR)	2000
Schedule 9 ईएमडी राशि/EMD Amount (In INR)	13680
Schedule 10 ईएमडी राशि/EMD Amount (In INR)	620
Schedule 11 ईएमडी राशि/EMD Amount (In INR)	1500
Schedule 12 ईएमडी राशि/EMD Amount (In INR)	1104
Schedule 13 ईएमडी राशि/EMD Amount (In INR)	1180
Schedule 14 ईएमडी राशि/EMD Amount (In INR)	1600
Schedule 15 ईएमडी राशि/EMD Amount (In INR)	372
Schedule 16 ईएमडी राशि/EMD Amount (In INR)	54056
Schedule 17 ईएमडी राशि/EMD Amount (In INR)	59850

ईपीबीजी विवरण /ePBG Detail

एडवाइजरी बैंक/Advisory Bank	State Bank of India
ईपीबीजी प्रतिशत (%)/ePBG Percentage(%)	3.00
ईपीबीजी की आवश्यक अवधि (माह) /Duration of ePBG required (Months).	12

(a). जेम की शर्तों के अनुसार ईएमडी छूट के इच्छुक बिडर को संबंधित केटेगरी के लिए बिड के साथ वैध समर्थित दस्तावेज़ प्रस्तुत करने है। एमएसई केटेगरी के अंतर्गत केवल वस्तुओं के लिए विनिर्माता तथा सेवाओं के लिए सेवा प्रदाता ईएमडी से छूट के पात्र हैं। व्यापारियों को इस नीति के दायरे से बाहर रखा गया है।/EMD EXEMPTION: The bidder seeking EMD exemption, must submit the valid supporting document for the relevant category as per GeM GTC with the bid. Under MSE category, only manufacturers for goods and Service Providers for Services are eligible for exemption from EMD. Traders are excluded from the purview of this Policy.

(b). The EMD Amount will be applicable for each schedule/group selected during Bid creation.

(c).ईएमडी और संपादन जमानत राशि, जहां यह लागू होती है, लाभार्थी के पक्ष में होनी चाहिए। / EMD & Performance security should be in favour of Beneficiary, wherever it is applicable.

(d).ईएमडी और संपादन जमानत राशि लाभार्थी के पक्ष में होनी चाहिए। / Earnest Money Deposit (EMD) shall also be accepted by the buyer in the form of a surety bond.

लाभार्थी /Beneficiary :
Account Officer
Directorate of Health Services, Health Department Andaman & Nicobar, N/A,
(Ddo)

बोली विभाजन लागू नहीं किया गया/ Bid splitting not applied.

एमआईआई खरीद वरीयता / MII Purchase Preference

एमआईआई खरीद वरीयता / MII Purchase Preference	Yes
मेक इन इंडिया विक्रेताओं को खरीद में प्राथमिकता, यदि उनका मूल्य L1+X% तक की सीमा में है / Purchase Preference to MII sellers availabele upto price within L1+X%	20
मेक इन इंडिया खरीद में प्राथमिकता के लिए बिड की मात्रा का अधिकतम प्रतिशत / Maximum Percentage of Bid quantity for MII purchase preference	50
सार्वजनिक खरीद (मेक-इन-इंडिया को प्राथमिकता) आदेश 2017 के अनुसार केवल क्लास 1/क्लास 2 के स्थानीय आपूर्तिकर्ताओं को ही भागीदारी की अनुमति है दिनांक 16.09.2020 (समय-समय पर संशोधित एवं लागू) / Allow participation only from Class 1/Class 2 local suppliers as per the Public procurement(Preference to Make-in-india) order 2017 date 16.09.2020(as amended and applicable time to time)	Yes, in compliance with the MII ORDER : DPIIT Order(as amended and applicable time to time)

एमएसई खरीद वरीयता/MSE Purchase Preference

एमएसई खरीद वरीयता/MSE Purchase Preference	Yes
सूक्ष्म और लघु उद्यम मूल उपकरण निर्माताओं/सेवा प्रदाता को खरीद में प्राथमिकता, यदि उनका मूल्य L1+X% / Purchase Preference to MSE OEMs/ Service Provider available upto price within L1+X%	15
सूक्ष्म और लघु उद्यम मूल उपकरण निर्माता/सेवा प्रदाता को खरीद में प्राथमिकता के लिए बिड की मात्रा का अधिकतम प्रतिशत / Percentage of Bid quantity/amount for MSE OEMs/ Service Provider Purchase preference	25

1. If the bidder is a Micro or Small Enterprise as per latest orders issued by Ministry of MSME, the bidder shall be relaxed from the eligibility criteria of "Experience Criteria" as defined above subject to meeting of quality and

technical specifications. The bidder seeking Relaxation from Experience Criteria, shall upload the supporting documents to prove his eligibility for Relaxation.
2. If the bidder is a Micro or Small Enterprise (MSE) as per latest orders issued by Ministry of MSME, the bidder shall be relaxed from the eligibility criteria of "Bidder Turnover" as defined above subject to meeting of quality and technical specifications. If the bidder itself is MSE OEM of the offered products, it would be relaxed from the "OEM Average Turnover" criteria also subject to meeting of quality and technical specifications. The bidder seeking Relaxation from Turnover, shall upload the supporting documents to prove his eligibility for Relaxation.
3. If the bidder is a DPIIT registered Startup, the bidder shall be relaxed from the the eligibility criteria of "Experience Criteria" as defined above subject to their meeting of quality and technical specifications. The bidder seeking Relaxation from Experience Criteria, shall upload the supporting documents to prove his eligibility for Relaxation.
4. If the bidder is a DPIIT registered Startup, the bidder shall be relaxed from the the eligibility criteria of "Bidder Turnover" as defined above subject to their meeting of quality and technical specifications. If the bidder is DPIIT Registered OEM of the offered products, it would be relaxed from the "OEM Average Turnover" criteria also subject to meeting of quality and technical specifications. The bidder seeking Relaxation from Turnover shall upload the supporting documents to prove his eligibility for Relaxation.
5. The minimum average annual financial turnover of the bidder during the last three years, ending on 31st March of the previous financial year, should be as indicated above in the bid document. Documentary evidence in the form of certified Audited Balance Sheets of relevant periods or a certificate from the Chartered Accountant / Cost Accountant indicating the turnover details for the relevant period shall be uploaded with the bid. In case the date of constitution / incorporation of the bidder is less than 3-year-old, the average turnover in respect of the completed financial years after the date of constitution shall be taken into account for this criteria.
6. Experience Criteria: In respect of the filter applied for experience criteria, the Bidder or its OEM of the product offered in the bid {themselves or through reseller(s)} should have regularly, manufactured and supplied same or similar Category Products to any Central / State Govt Organization / PSU for number of Financial years as indicated above in the bid document before the bid opening date. Copies of relevant contracts and delivery acceptance certificates like CRAC to be submitted along with bid in support of having supplied some quantity during each of the Financial year. In case of bunch bids, the category of primary product having highest value should meet this criterion.
7. OEM Turn Over Criteria: The minimum average annual financial turnover of the OEM of the offered product during the last three years, ending on 31st March of the previous financial year, should be as indicated in the bid document. Documentary evidence in the form of certified Audited Balance Sheets of relevant periods or a certificate from the Chartered Accountant / Cost Accountant indicating the turnover details for the relevant period shall be uploaded with the bid. In case the date of constitution / incorporation of the OEM is less than 3 year old, the average turnover in respect of the completed financial years after the date of constitution shall be taken into account for this criteria.
8. Preference to Make In India products (For bids < 200 Crore):Preference shall be given to Class 1 local supplier as defined in public procurement (Preference to Make in India), Order 2017 as amended from time to time and its subsequent Orders/Notifications issued by concerned Nodal Ministry for specific Goods/Products. The minimum local content to qualify as a Class 1 local supplier is denoted in the bid document. If the bidder wants to avail the Purchase preference, the bidder must upload a certificate from the OEM regarding the percentage of the local content and the details of locations at which the local value addition is made along with their bid, failing which no purchase preference shall be granted. In case the bid value is more than Rs 10 Crore, the declaration relating to percentage of local content shall be certified by the statutory auditor or cost auditor, if the OEM is a company and by a practicing cost accountant or a chartered accountant for OEMs other than companies as per the Public Procurement (preference to Make-in -India) order 2017 dated 04.06.2020. Only Class-I and Class-II Local suppliers as per MII order dated 4.6.2020 will be eligible to bid. Non - Local suppliers as per MII order dated 04.06.2020 are not eligible to participate. However, eligible micro and small enterprises will be allowed to participate .The buyers are advised to refer the OM No.F.1/4/2021-PPD dated 18.05.2023.
OM_No.1_4_2021_PPD_dated_18.05.2023 for compliance of Concurrent application of Public Procurement Policy for Micro and Small Enterprises Order, 2012 and Public Procurement (Preference to Make in India) Order, 2017 and its subsequent Orders/Notifications issued by concerned Ministry .Benefits of MSE will be allowed only if seller/service provider is validated on-line in GeM profile as well as validated and approved by Buyer after evaluation of documents submitted.

9. Purchase preference to Micro and Small Enterprises (MSEs): Purchase preference will be given to MSEs having valid Udyam Certificate and whose credentials are validated online through Udyam Registration portal as defined in Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 dated 23.03.2012 issued by Ministry of Micro, Small and Medium Enterprises and its subsequent Orders/Notifications issued by concerned Ministry. If the bidder wants to avail themselves of the Purchase preference, the bidder must be the manufacturer / OEM of the offered product on GeM. In respect of bid for Services, the bidder must be the Service provider of the offered Service. Traders are excluded from the purview of Public Procurement Policy for Micro and Small Enterprises and hence resellers offering products manufactured by some other OEM are not eligible for any

purchase preference. Relevant documentary evidence in this regard shall be uploaded along with the bid in respect of the offered product or service, and Buyer will decide eligibility for purchase preference based on documentary evidence submitted in case of product bids, whereas in case of services the eligibility is automatically validated. If L-1 is not an MSE and MSE Seller (s) has / have quoted price within L-1+ 15% (Selected by Buyer) of margin of purchase preference /price band defined in relevant policy, such MSE Seller shall be given opportunity to match L-1 price and contract will be awarded for 25% (selected by Buyer) percentage of total quantity. The buyers are advised to refer the OM_No.1_4_2021_PPD_dated_18.05.2023 for compliance of Concurrent application of Public Procurement Policy for Micro and Small Enterprises Order, 2012 and Public Procurement (Preference to Make in India) Order, 2017. Benefits of MSE will be allowed only if seller is validated on-line in GeM profile as well as validated and approved by Buyer after evaluation of documents submitted.
10. Estimated Bid Value indicated above is being declared solely for the purpose of guidance on EMD amount and for determining the Eligibility Criteria related to Turn Over, Past Performance and Project / Past Experience etc. This has no relevance or bearing on the price to be quoted by the bidders and is also not going to have any impact on bid participation. Also this is not going to be used as a criteria in determining reasonableness of quoted prices which would be determined by the buyer based on its own assessment of reasonableness and based on competitive prices received in Bid / RA process.

11. Reverse Auction would be conducted amongst all the technically qualified bidders except the Highest quoting bidder. The technically qualified Highest Quoting bidder will not be allowed to participate in RA. However, H-1 will also be allowed to participate in RA in following cases:

i. If number of technically qualified bidders are only 2 or 3.
ii. If Buyer has chosen to split the bid amongst N sellers, and H1 bid is coming within N.
iii. In case Primary product of only one OEM is left in contention for participation in RA on elimination of H-1.
iv. If L-1 is non-MSE and H-1 is eligible MSE and H-1 price is coming within price band of 15% of Non-MSE L-1
v. If L-1 is non-MII and H-1 is eligible MII and H-1 price is coming within price band of 20% of Non-MII L-1

मूल्यांकन विधि(मदवार मूल्यांकन विधि) / **Evaluation Method** (Item Wise Evaluation Method)

Contract will be awarded schedule wise and the determination of L1 will be done separately for each schedule. The details of item-consignee combination covered under each schedule are as under:

मूल्यांकन अनुसूचियां / **Evaluation Schedules**	वस्तु/श्रेणी / **Item/Category**	मात्रा / **Quantity**
Schedule 1	Noradrenaline Injection	10000
Schedule 2	Adrenaline Injection (v2)	8000
Schedule 3	Lignocaine Injection	3000
Schedule 4	Isoflurane Liquid For Inhalation	100
Schedule 5	Dexamethasone Injection	30000
Schedule 6	Dobutamine Injection	2000
Schedule 7	Fentanyl Injection	4000
Schedule 8	Hyoscine Butyl Bromide Injection	20000
Schedule 9	Levetiracetam Injection	6000
Schedule 10	Morphine Injection	2000
Schedule 11	Phenytoin Injection	15000
Schedule 12	Adenosine Injection (v2)	1200
Schedule 13	Amiodarone Injection (v2)	1000
Schedule 14	Atracurium Injection (v2)	2000
Schedule 15	Betamethasone Injection (v2)	2000
Schedule 16	Erythropoietin Injection	20000

Schedule 17	Erythropoietin Injection	10000

Noradrenaline Injection (10000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Noradrenaline
	Dosage Form	Injection
	Strength	2 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	5000	1	30
			5000	180	210

Adrenaline Injection (V2) (8000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Adrenaline
	Dosage Form	Injection
	Strength	1 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	1 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	4000	1	30
			4000	180	210

Lignocaine Injection (3000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Lignocaine
	Dosage Form	Injection
	Strength	2%
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Vial
	Primary pack size	30 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	1500	1	30
			1500	180	210

Isoflurane Liquid For Inhalation (100 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

[* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification]

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Isoflurane
	Dosage Form	Liquid for inhalation
PACKAGING	Type of primary packing	Bottle
	Primary pack size	250 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	मात्रा /Quantity: 100 / डिलीवरी के दिन/Delivery Days: 45

Dexamethasone Injection (30000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

[* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification]

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Dexamethasone
	Dosage Form	Injection
	Strength	4 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule, Vial
	Primary pack size	2 ml

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	मात्रा /Quantity / प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after / डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by 15000 / 1 / 30 15000 / 180 / 210

Dobutamine Injection (2000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

[* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification]

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Dobutamine
	Dosage Form	Injection
	Strength	50 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	5 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)	
			मात्रा /Quantity	डिलीवरी के दिन/Delivery Days
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	2000	45

Fentanyl Injection (4000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Fentanyl
	Dosage Form	Injection
	Strength	50 mcg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	2000	1	30
			2000	180	210

Hyoscine Butyl Bromide Injection (20000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local

Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

[* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification]

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Hyoscine Butyl Bromide
	Dosage Form	Injection
	Strength	20 mg/ mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	1 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
			10000	1	30
			10000	180	210

Levetiracetam Injection (6000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Levetiracetam
	Dosage Form	Injection
	Strength	100 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Vial
	Primary pack size	5 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	3000	1	30
			3000	180	210

Morphine Injection (2000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Morphine
	Dosage Form	Injection
	Strength	15 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	1 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	1000	1	30
			1000	180	210

Phenytoin Injection (15000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

[* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification]

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Phenytoin
	Dosage Form	Injection
	Strength	50 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2 ml

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	मात्रा /Quantity / प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after / डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by 10000 / 1 / 30 5000 / 180 / 210

Adenosine Injection (V2) (1200 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Adenosine
	Dosage Form	Injection
	Strength	3 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)	
			मात्रा /Quantity	डिलीवरी के दिन/Delivery Days
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	1200	45

Amiodarone Injection (V2) (1000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Amiodarone
	Dosage Form	Injection
	Strength	50 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	3 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)	
			मात्रा /Quantity	डिलीवरी के दिन/Delivery Days
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	1000	45

Atracurium Injection (V2) (2000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Atracurium
	Dosage Form	Injection
	Strength	10 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2.5 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)	
			मात्रा /Quantity	डिलीवरी के दिन/Delivery Days
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	2000	45

Betamethasone Injection (V2) (2000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Betamethasone
	Dosage Form	Injection
	Strength	4 mg/mL
	Compliance to uploaded Special Terms and Conditions	Yes
PACKAGING	Type of primary packing	Ampoule
	Primary pack size	2 ml
CERTIFICATIONS & REPORTS	Availability of valid drug manufacturing license issued from the competent authority defined under Drugs and Cosmetic Act and Rules there under as amended till date	Yes
	Submission of all necessary certifications, licenses and test reports to the buyer as per buyer requirement at the time of bid submission and along with supplies	Yes
SHELF LIFE	Shelf life in months from the date of manufacture	24, 36 Or higher **(month)**

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)	
			मात्रा /Quantity	डिलीवरी के दिन/Delivery Days
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	2000	45

Erythropoietin Injection (20000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Erythropoietin
	Strength	4000 IU
	Compliance to uploaded Special Terms and Conditions	Yes

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	10000	1	30
			10000	180	210

Erythropoietin Injection (10000 pieces)

(क्रमशः श्रेणी 1 और श्रेणी 2 के स्थानीय आपूर्तिकर्ता के रूप में अर्हता प्राप्त करने के लिए आवश्यक/Minimum 50% and 20% Local Content required for qualifying as Class 1 and Class 2 Local Supplier respectively)

तकनीकी विशिष्टियाँ /Technical Specifications

* जेम केटेगरी विशिष्टि के अनुसार / As per GeM Category Specification

विवरण/Specification	विशिष्टि का नाम /Specification Name	बिड के लिए आवश्यक अनुमत मूल्य /Bid Requirement (Allowed Values)
PRODUCT INFORMATION	Medicine Name	Erythropoietin
	Strength	10000 IU/mL
	Compliance to uploaded Special Terms and Conditions	Yes

परेषिती/रिपोर्टिंग अधिकारी तथा मात्रा/Consignees/Reporting Officer and Quantity

क्र.सं./S.No.	परेषिती/रिपोर्टिंग अधिकारी /Consignee Reporting/Officer	पता/Address	डिलीवरी अनुसूची /Delivery Schedule अनुबंध prarambh होने की तारीख से दिनों की संख्या में /(In number of days from contract start days)		
			मात्रा /Quantity	प्रारंभ होने की तारीख से डिलीवरी /Delivery to start after	डिलीवरी _____तक पूरी कर ली जाए /Delivery to be completed by
1	Manoj Das	744104,Central Medical Store, Directorate of Health Services Andaman & Nicobar Administration	5000	1	30
			5000	180	210

Special terms and conditions-Version:1 effective from 24-05-2024 for category Noradrenaline Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted

product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.

16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
    1. Generic name of the product
    2. Batch No.

3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation

from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the “NOT OF STANDARD QUALITY ITEMS” after the expiry of 45 days.

Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder

as under:

"The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee's site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

- Sl. No. & Date
- Nomenclature & Specification
- Name & Address of Manufacturing Unit
- Batch No.
- DOM & DOE
- Qty. of each batch
- Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

- Minimum delivery period will be of 45 days from the date of issuing of the purchase
- The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.

- The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 06-07-2023 for category Adrenaline Injection (V2)

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.

5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central

Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.

18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not

to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Lignocaine Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the "Notarized Undertaking" in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____("Product") and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online 'SUGAM' portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturers products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

    b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

    c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients

and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the sellers risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:2 effective from 14-11-2025 for category Isoflurane Liquid for Inhalation

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____("Product") and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online 'SUGAM' portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine

quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government’s Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government’s Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.

22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

    b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

    c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

    - The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
    - The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
    - **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in

each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to

drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.

- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Dexamethasone Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to

offer the same for sale through the GeM portal.

3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online 'SUGAM' portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer.

However, one bidder will be allowed to submit only one offer for one product.

11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government’s Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government’s Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of

the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

1. Generic name of the product
2. Batch No.
3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**

- Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
- Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

  “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

  On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and

Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Dobutamine Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-‘M’ for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever

required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)

15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

1. Generic name of the product
2. Batch No.
3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the

supplier whether consumed fully/partially.

- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the “NOT OF STANDARD QUALITY ITEMS” after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

    - If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

- Minimum delivery period will be of 45 days from the date of issuing of the purchase
- The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
- The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Fentanyl Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of

Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.

4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement

agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.

17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the

individual tests should be given
10. Conclusion
11. Qualified Person’s signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer’s right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods.”

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the “NOT OF STANDARD QUALITY ITEMS” after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the

above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and

applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Hyoscine Butyl Bromide Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with

all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the

stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Levetiracetam Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g.,

validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.

2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per

revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.

8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

    b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

    c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

    - The Buyer may engage the services of a Quality Control Agent & Quality Control Testing

Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.

- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months

period shall be acceptable.

- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Morphine Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____("Product") and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online 'SUGAM' portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government’s Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government’s Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of

Drugs and Cosmetics Rules, 1945 as amended up to date.

In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

1. Generic name of the product
2. Batch No.
3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**

- Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
- Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

  “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

  On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 14-11-2025 for category Phenytoin Injection

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on

the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.

5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-‘M’ for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).

12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the

pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**

- All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

1. Generic name of the product
2. Batch No.
3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

"Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared "NOT OF STANDARD QUALITY", by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**

- Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
- Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

"The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee's site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 06-07-2023 for category Adenosine Injection (V2)

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted

product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.

16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
    1. Generic name of the product
    2. Batch No.

3. Pharmacopoeia Reference and/ or In-house method
4. Batch quantity
5. Date of manufacture
6. Expiry date
7. Date of test
8. Description (clarity, color etc)
9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
10. Conclusion
11. Qualified Person's signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation

from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the “NOT OF STANDARD QUALITY ITEMS” after the expiry of 45 days.

Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder

as under:

“The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

- Minimum delivery period will be of 45 days from the date of issuing of the purchase
- The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been

maintained, supply against the said order is liable to be rejected and cancelled.
- The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 06-07-2023 for category Amiodarone Injection (V2)

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also

be applicable in case of Narcotic Drugs & Psychotropic Substances.

5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturers products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.

17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:
    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion

11. Qualified Person’s signature

The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

- Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer’s right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods.”

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be “Not of Standard Quality” or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the “NOT OF STANDARD QUALITY ITEMS” after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied

drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or

have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee's site.

On such rejection, the stores will be at the sellers risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall

supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:2 effective from 13-11-2025 for category Atracurium Injection (V2)

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per revised Schedule-'M' for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule "L1" of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government's Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply

of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs "not of standard", "Grossly sub-standard" and "Spurious and adulterated drugs" as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

- The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months period shall be acceptable.
- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the

stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:1 effective from 06-07-2023 for category Betamethasone Injection (V2)

1. 1. The sellers are registered on GeM and exempted from the Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g.,

validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.

2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____(“Product”) and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online ‘SUGAM’ portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP/WHO-GMP Certificate of the manufacturing site as per

revised Schedule-‘M’ for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.

8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

   This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
14. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
15. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government’s Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
16. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government’s Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
17. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
18. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
19. Bidder/seller should submit a notarized undertaking on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues &legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the latest guidelines issued by the Drug Controller of India from time to time.

20. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
21. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.
22. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
23. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

24. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

25. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines supplied shall be accompanied with in-house **Test Report/Certificate of Analysis** from the manufacturer's own Quality Control Lab. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - Buyer will embark on stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage

    b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

    c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

    - The Buyer may engage the services of a Quality Control Agent & Quality Control Testing

Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.

- The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to the goods dispatch from the place of manufacture.
- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."

- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, and the report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the buyer. In case of any complaint in the field, the B.M.R/ B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. For New drugs/medicines, complete stability data of 6 months

period shall be acceptable.

- The case of admixture of drugs will be treated as a violation of terms and conditions and will not be accepted.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.
- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

26. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

27. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

28. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

29. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

Sl. No. & Date	Nomenclature & Specification	Name & Address of Manufacturing Unit	Batch No.	DOM & DOE	Qty. of each batch	Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

30. **Packaging, Labelling and Marking Requirements**

    Packaging, Labelling and Marking shall be as per the provisions contained in the Drugs and Cosmetics Act, 1940 and the Rules made there under as amended up-to-date, other particulars of packaging, labelling & marking, if any, prescribed by the buyer in the bid through Additional Terms and Conditions (ATC) shall be complied with.

31. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

32. **Delivery Period**

    - Minimum delivery period will be of 45 days from the date of issuing of the purchase
    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

33. Any specific requirements for the packaging, labelling, logograms, printing, artwork, bar coding or any other requirement mentioned by the buyer through Additional Terms and Conditions (ATC) in the bid will be applicable.
34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

Special terms and conditions-Version:2 effective from 07-08-2026 for category Erythropoietin Injection

1. 1. The sellers are registered on GeM and exempted from the video assessment of Vendor Assessment process based on the undertaking & submitted copy of a valid Manufacturing Drug License certified by the issuing authority. Buyers must mandatorily ask for submitting the relevant valid drug license and other regulatory documents applicable with the bid. Buyers must also check and validate the details e.g., validity, authenticity/genuineness, name of the drug/medicine under procurement, the license issuing authority etc. at their end.
   2. The Buyer shall ask the seller to submit the “Notarized Undertaking” in the mentioned below format (scanned copy and hard copy). Details of the same may be verified by the buyer at their end.

UNDERTAKING

(to be on non-judicial stamp paper of Rs 10 and notarized)

I, _____, s/o / d/o / w/o _____, aged about _____resident of _____, do hereby declare and undertake that;

1. I am the partner / proprietor / director of _____ *(name of entity)* and duly authorized to sign this undertaking on behalf of _____. *(Name of entity)*
2. We are the manufacturers of the drug/medicine _____("Product") and intend to offer the same for sale through the GeM portal.
3. We state that the license for the Product has been granted/obtained by us as per the provisions of the Drug & Cosmetics Act, 1940 and rules framed there under as amended till date.
4. We further state that the details regarding the Product/licenses have been uploaded by us on the online 'SUGAM' portal of CDSCO as per rule 84AB of the Drugs and Cosmetics Rules, 1945 as amended till date. Reference no. for SUGAM portal is_____.
5. We undertake that all the information provided above is true and complete in all respect. We understand that in the event any false information/declaration is provided by us, suitable legal action/action as per Drugs and Cosmetics Act, 1940 as amended till date and rules made there under will be initiated.

Place:

Date:

.....

Signature, Name, Designation & Seal

on behalf of the Manufacturer

3. All Provisions of Drugs and Cosmetics Act, 1940 and Rules made there under as amended till date will always be applicable. This will include all notifications issued by *Central Drugs Standard Control Organization* (*CDSCO*), Ministry of Health & Family Welfare (MoHFW) and Department of Pharmaceuticals (DOP), Ministry of Chemicals & Fertilizers time to time in this regard.
4. All provisions of Narcotic Drugs & Psychotropic Substances Act, 1985 as amended till date will also be applicable in case of Narcotic Drugs & Psychotropic Substances.
5. The purchase shall be made through Bidding/RA only irrespective of the value.
6. Manufacturer shall have a valid own manufacturing license issued by the competent drug licensing authority defined under the Drugs and Cosmetics Act 1940 and Rules made there under as amended till date. The Drug/medicine quoted should be clearly marked and highlighted in Drug Manufacturing License. The valid own manufacturing license shall be submitted to the buyer at the time of bid submission/delivery as per buyer requirement.

   In case of authorized resellers/distributors, it will be the legal & regulatory liability of the manufacturer to ensure that their authorized resellers/distributors are operating in compliance with all relevant laws and regulations and are properly licensed to sell the manufacturer's products.

   Manufacturer shall be responsible for verifying the validity and authenticity of drug license held by their authorized resellers/distributors.

   If revalidation of drug license has been applied for, the buyer shall be informed accordingly and the copy of application to State Drug / Licensing authority must be submitted with a certificate that application for renewal was made within time frame as per Drug and Cosmetic Act as amended up to date and that has not been deleted by drug licensing authority.

7. Bidder/Seller shall submit the valid GMP Certificateas per revised Schedule-'M'/WHO-GMP Certificate of the manufacturing site for the quoted drugs/medicines issued by the Concerned Drug Licensing Authority to the buyer at the time of bid submission.
8. Bidder/Seller shall submit a valid **non-Conviction** certificate for last two (2) consecutive years issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of technical opening of the bid.
9. Bidder/Seller shall submit **Manufacturing & Market Standing certificate** (in India) issued by the concerned drug licensing authority for at least latest 2 consecutive years for the drug/medicine quoted to the buyer at the time of bid submission. The drug/medicine quoted should be clearly marked and highlighted.

This would not apply to drugs, which were introduced in India less than 2 years ago. A certificate from the Drug Controller General (India) shall be required for all new drug formulations to this effect.

10. If a company/firm has two or more separate manufacturing units at different sites / States/region, which are not separate entities then the company will be allowed to submit only one bid for all units but necessary document regarding separate manufacturing units will be submitted to the buyer. However, one bidder will be allowed to submit only one offer for one product.
11. The manufacturer shall have in house testing facilities and valid Good Laboratory Practice (GLP Certificate) as per Schedule “L1” of the Drugs & Cosmetics Act and Rules made thereunder as amended up to date issued by Central / State Drug Controller / FDA for the quoted drugs/medicines (as applicable).
12. Bidder/Seller shall have Maximum Production Capacity Certificate (section wise) issued by concerned drug licensing authority highlighting the quoted product.
13. Products included in the Indian Pharmacopoeia (I.P.) must strictly comply with I.P. standards. Products not covered under I.P. shall conform to other recognized official pharmacopoeial standards (BP/USP) or as approved by CDSCO/Drug Control Authority.
14. STP (Standard Testing Procedure) along with the required reference standards for non-Pharmacopoeia drugs/medicines are required to be submitted by the bidder/seller at the time of submission of the bid.
15. The bidder/seller shall submit complete stability data (long term stability studies and accelerated stability studies) for all drugs/medicines in specified packing for at least 3 batches whenever required by the buyer. For New drugs/medicines, complete stability data of 6 months period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)
16. The bidder/seller should have not been blacklisted/debarred/de-registered/banned for the quoted product by any State Government / Central Government / Central or State Government’s Drug procurement agencies at the time of submission of bid. Further, quoted drugs / medicines have not been failed in house testing or testing by any State Government / Central Government / its Drug procurement agencies during last two years. If any bidder/seller has been blacklisted / debarred / de-registered/banned due to quality failure, such bidder/seller or their Partner / Director / Owner shall not be permitted to participate in the bid.
17. During the validity of the bid if the firm/Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government/Central or State Government’s Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to the buyer along with relevant authentic document by the bidder/seller firm/ company within one month.
18. During Contract period, if the supplier is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, buyer may cancel the contract and go for fresh bid as per discretion of the buyer.
19. The firm/company/ corporation and any of its director/proprietors/ partners/ Authorized signatories should not be convicted/ or a criminal case filed against or pending in any court of India by any department of Govt. under prevention of Corruption Act or for cheating/ defrauding Government/ embezzlement of Government fund or any criminal conspiracy in the said matter at the time of submission of bid.
20. Bidder/seller should submit a notarized undertaking to the buyer as per buyer's requirement on an affidavit of Rs. 100/- (Rupees One Hundred only) duly attested by the Notary stating that:

    They will comply with all the statues & legislation regarding manufacturing, import, sale, and supply of drugs in India and in particular the following Acts/Enactments viz., The Drugs and Cosmetics Act, 1940, The Drugs and Cosmetics Rules, 1945 (as amended), The Legal Metrology Act, 2009, The Drugs (Control) Act, 1950, The Indian Statistical Institute Act, 1959, GST Act.

    To supply drugs of standard quality as prescribed under the provisions of Drug and Cosmetic Act, 1940 (as amended). The bidder shall also undertake not to supply items/drugs “not of standard”, “Grossly sub-standard” and “Spurious and adulterated drugs” as per the latest guidelines issued by the Drug Controller of India from time to time.

21. The price offered by the seller/bidder shall not, in any case, exceed the DPCO/NPPA controlled price or price fixed by the State Government, if any. The seller must reduce the prices if there is any reduction in DPCO/NPPA ceiling price or price fixed by State Government, if any.
22. Guidelines of Department of Pharmaceuticals applicable as nodal ministry for implementing the provision of Public Procurement (Preference to Make in India) order (PPO) 2017-revision as amended to date, related to procurement of Goods & Services in Pharmaceutical Formulations, will be applicable.

23. **Fall Clause**: Provision of fall clause will not be applicable on the sale of drugs which have an expiry date as per Ministry of Chemical and Fertilizer OM No 31026/1/2019-Policy dated 12-9-2020.
24. **Shelf Life:** Shelf life of each quoted drugs/medicines shall be in accordance with Schedule P of Drugs and Cosmetics Rules, 1945 as amended up to date.

    In case pre-dispatch inspection is not applicable, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drug/medicine at the time of delivery to the consignee.

    In case of pre-dispatch inspection, at the time when the stores are offered for inspection, the life of the drugs/medicines shall not have passed more than one sixth (1/6th) of the total shelf life of the drugs/medicines.

25. **Recalls**

    If products are recalled because of problems with product quality or adverse reaction to the pharmaceutical, the supplier will be obliged to notify the buyer, providing full details about the reason leading to the recall, and shall take steps to replace the product in question at suppliers own cost at the ultimate destination with a fresh batch of acceptable pharmaceuticals or withdraw and give a full refund of the unconsumed quantity if the product has been taken off the market due to safety problems.

26. **Inspection, Testing and Quality Control**
    - All the batches of the drugs/medicines/vaccines supplied shall be accompanied with Test Report/Certificate of Analysis from manufacturer's own Quality Control Lab or NABL Accredited Lab or Government-approved laboratories. The Test Report/Certificate of Analysis shall include:

    1. Generic name of the product
    2. Batch No.
    3. Pharmacopoeia Reference and/ or In-house method
    4. Batch quantity
    5. Date of manufacture
    6. Expiry date
    7. Date of test
    8. Description (clarity, color etc)
    9. All identity, potency, purity, sterility, pyrogen and all other test required by the specified pharmacopoeia and/or In-house method. Both the actual results and the limits for the individual tests should be given
    10. Conclusion
    11. Qualified Person's signature

    The above-mentioned batch shall be manufactured in accordance with the applicable GMP regulations.

    - The buyer may carry out stringent quality checks to ensure that drugs/medicines/goods meet required standards throughout specified shelf life. The buyer reserves the right to carry necessary inspections/tests from NABL Accredited/Government approved laboratories at any of, or any combination of or/ all following stages:

    a) At Pre-Dispatch stage: prior to direct shipment to the consignees from supplier's premises/warehouse.

    b) At Delivery Stage: Inspection done once the drugs/medicines/goods reach at consignee location and before taking over supplied goods in inventory.

    c) Post Delivery Surveillance: The Drugs/Medicines/goods shall have the active ingredients and all other parameters at the prescribed level as indicated in official compendiums or technical specifications throughout the shelf-life period of the drugs/medicines/ goods. Quality Monitoring Activities may also be organized by the buyer post-delivery.

    - The Buyer may engage the services of a Quality Control Agent & Quality Control Testing Laboratories for the purpose of Inspection & Quality Control. The sampling quantities shall be borne by the supplier.
    - The buyer's right to inspect, test and, where necessary reject the drugs/medicines/goods after the drugs/medicines/goods arrival at the final destination shall in no way be limited or waived by reason of the goods having previously been inspected, tested and passed prior to

the goods dispatch from the place of manufacture.

- **Inspection Methodology**: At pre-dispatch and/or delivery stage, samples of supplies in each batch will be chosen for testing. The samples will be collected and sent to designated laboratories (NABL Accredited/Government approved laboratories) for testing as decided by the buyer.

  Handling and testing charges for this purpose shall be borne by the Buyer *for the above purpose*.

- The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories.

  At post-delivery surveillance - The samples will be collected from the warehouse of buyer/or final consignee in States/UTs and sent to designated Quality Control Labs in respect of supplied drugs/medicines/goods at any point during specified shelf life as per decision of the buyer.

  Handling and testing charges will be borne by the buyer for the above purpose.

- In case of failure of batches during or at any stage (indicated above), the testing charges would be claimed for the defaulting vendor.
- "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/ batches will be deemed to be rejected goods."
- **At any of testing stage**, Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected drugs/medicines/goods and the cost of entire batch paid will be recovered from the supplier whether consumed fully/partially.
- If any inspected or tested drugs/medicines/goods fails to conform to the specifications or fails in quality tests, the buyer may reject them, and the supplier will be responsible to take back the rejected drugs/medicines/goods from the depots/consignee place at their own cost and replace with fresh stock duly inspected and tested within 45 days from the date of intimation from the buyer to the supplier or as specified by the buyer. The buyer has the right to destroy such rejected drugs/medicines/goods if the supplier does not take back the drugs/medicines/goods within the stipulated time. The buyer will arrange to destroy the "NOT OF STANDARD QUALITY ITEMS" after the expiry of 45 days.

  Action may also be initiated by the buyer for debarring/blacklisting against the supplier for suitable period. The FDA/ Drugs Control Authority of concerned State will also be informed by the buyer for initiating necessary action on the supplier in their state. In addition, Security deposit will also be forfeited without any intimation.

  The decision of the buyer or any officer authorized by buyer, as to the quality of the supplied drugs, medicines etc., shall be final and binding.

- In case any drug/medicine is found substandard either any of testing stage or during the shelf life of the item, the report of the NABL/Government approved laboratory shall be accepted by the supplier/seller. If the same is disputed by the supplier/seller giving the reasons, the sample will be sent to Central Drug Laboratory, Kolkata, or the Designated CDL for the product. The report of CDL will only be accepted as final and conclusive report. However, the same should be submitted within three months, from the date of communication of the disputed test report to the supplier/seller. For this, supplier/seller should approach the concerned Drug Control Authorities for getting the drugs/medicines tested, as per procedure, from the Appellate Laboratory at their own cost.

  The de-registration / debarment action will be taken by the buyer against the manufacturing unit and contract holding firms (both) according to the category-A and category-B defects as per guidelines issued by the Ministry of Health & Family Welfare, Government of India and same will be communicated to GeM.

- The Batch Manufacturing Record (BMR/BPR) and the Master Formulation Record (MFR) for all products shall be provided by the Supplier/Seller as and when requested by the Buyer.
- Statutory provisions on manufacture, distribution, storage and quality issues of drugs/medicines under the Drugs & Cosmetic Act, 1940 as amended up to date is vested with the DCGI (CDSCO)/ MoH& FW, including its Central/ Zonal/ Regional Drug Testing Labs. Similarly, the authority for confiscation, sealing or prosecution with relation to

drugs/medicines under the said Act is also with the DCGI/ State Drug Control Authorities.

- In accordance with the provisions of Sec 22 & 31 of the Drugs and Cosmetic Act, 1940, as amended up to date, the DCGI/ CDSCO/ State Drug Controller/ Drug Inspector may exercise their powers as an Inspecting Agency.

27. **Deduction, Blacklisting, and other penalties on account of Quality failure**

    The suitable conditions may be added by the buyer in the bid through Additional Term & Conditions (ATC) as applicable.

28. **Quality Test by Statutory Authorities:**

    If any batch of any product(s) supplied by the supplier is declared “NOT OF STANDARD QUALITY”, by any government agencies or drug licensing authority, the supplier shall inform the same immediately to the buyer so that the use of the available stock of the particular item will be stopped. Further, the available stock of the product with all consignee/users will be retrieved.

29. **Termination for Default**

    The buyer may without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, terminate the contract in whole or in part If the supplier fails to promptly replace any drug/medicine/goods rejected submitted for testing or subject to recall ordered by the applicable Regulatory Authority in the country of manufacture due to unacceptable quality or reports of adverse drugs reaction after giving prompt notice of the recall.

30. **Warranty**
    - Supplies must fully comply in all respect with the Technical specifications and conditions laid down in the contract and in accordance with the Pharmacopoeia standards.
    - Each supply should be accompanied with a "Warranty Certificate" duly signed by the Bidder as under:

      “The Supplier/Seller hereby declares that the stores as detailed below sold to the buyer under this contract shall be of the best quality and workmanship and shall be strictly in accordance with the specifications and particulars mentioned and the supplier/seller hereby guarantees that the stores would continue to conform to the description of and quality aforesaid for a period of useful life of minimum of five sixth (5/6th) of the specified shelf life from the date of delivery of the said stores to the buyer, have overages within the ranges set forth in the technical specification and are not subject to recall by the applicable Regulatory Authority due to unacceptable quality or adverse Pharmaceuticals reaction. Notwithstanding the above, the fact that the said stores fail to conform to the description and quality aforesaid or have deteriorated and the decision of the buyer in that behalf is final and conclusive, the buyer will be entitled to reject the said stores, or such part thereof as may be discovered not to conform to the said description and quality. Losses due to premature deterioration due to biological and other activities during life potency will be made good and supplied by the firm at its own cost at consignee’s site.

      On such rejection, the stores will be at the seller's risk and all provisions herein contained relating to the rejection of stores shall apply. The supplier/Seller shall if so called upon to do so by the buyer in writing, replace the stores free of cost at the ultimate destination within a period of forty five days or such further period as may be extended from time to time by the buyer at his discretion, on application made there under by the supplier/seller after the stores or such portion of the stores thereof as is rejected by the buyer and in such an event the above mentioned warranty period shall apply to the stores replaced from the date of the replacement thereof otherwise the supplier/seller shall pay to the buyer such damage as may arise by reason of the breach of the conditions. Nothing herein contained shall prejudice any other rights of the buyer in that behalf under this contract or otherwise".

    - Sl. No. & Date
    - Nomenclature & Specification
    - Name & Address of Manufacturing Unit
    - Batch No.
    - DOM & DOE
    - Qty. of each batch
    - Remarks

Signature name & designation and date with rubber stamp

- If the supplier, having been notified, fails to replace within the period specified above, the buyer may proceed to take such remedial action(s) as may be necessary/deemed fit by the buyer, at the suppliers' risk and expense and without prejudice to other rights which the buyer may have against the supplier under the contract.

31. **Packaging, Labelling and Marking Requirements**

    The Packaging, Labelling, and Marking of drugs, medicines, and vaccines shall strictly conform to the provisions of the Drugs and Cosmetics Act, 1940 and the Rules made thereunder, as amended from time to time. In addition, any further requirements in respect of packaging, labelling, logograms, printing, artwork, or marking, as may be stipulated by the Buyer in the bid through Additional Terms and Conditions (ATC), shall also be complied with by the Supplier.

32. **Bar Coding**

    All drugs/medicines supplied should incorporate GS1 barcodes standards at various packaging levels (primary, secondary, and tertiary level packaging) and should encode the information within the barcodes as mentioned by the buyers in addition to other existing statutory labelling and marking requirements. Details of bar-coding will be given by the buyer through Additional Terms and Conditions (ATC) in the bid.

33. **Delivery Conditions**

    - The supplier should maintain the recommended temperature of the drug/medicine (wherever indicated) during transit, otherwise if on checking it is found that temperature has not been maintained, supply against the said order is liable to be rejected and cancelled.
    - The items requiring special cold storage conditions shall be supplied with cold chain transporting system under cold chain norms from the manufacturing unit to the warehouses/consignee location.

34. Any other Terms and Conditions which is not included or at variance with the conditions specified in STC & GTC, may be added by the buyer through Additional Terms and Conditions (ATC) in the bid to ensure drugs/medicines are procured from authentic/validated source with appropriate and applicable quality. The above terms and conditions are in reverse order of precedence i.e., ATC shall supersede specific Special Terms and Condistions (STC) which shall supersede General Terms and Conditions (GTC), whenever there are any conflicting provisions.

क्रेता द्वारा जोड़ी गई बिड की विशेष शर्तें/Buyer Added Bid Specific Terms and Conditions

1. **Generic**

   OPTION CLAUSE: The Purchaser reserves the right to increase or decrease the quantity to be ordered up to 25 percent of bid quantity at the time of placement of contract. The purchaser also reserves the right to increase the ordered quantity up to 25% of the contracted quantity during the currency of the contract at the contracted rates. The delivery period of quantity shall commence from the last date of original delivery order and in cases where option clause is exercised during the extended delivery period the additional time shall commence from the last date of extended delivery period. The additional delivery time shall be (Increased quantity ÷ Original quantity) × Original delivery period (in days), subject to minimum of 30 days. If the original delivery period is less than 30 days, the additional time equals the original delivery period. The Purchaser may extend this calculated delivery duration up to the original delivery period while exercising the option clause. Bidders must comply with these terms.

2. **Forms of EMD and PBG**

   Bidders can also submit the EMD with Fixed Deposit Receipt made out or pledged in the name of A/C

   Account Officer, DHS, Sri Vijaya Puram
   . The bank should certify on it that the deposit can be withdrawn only on the demand or with the sanction of the pledgee. For release of EMD, the FDR will be released in the favour of the bidder by the Buyer after making endorsement on the back of the FDR duly signed and stamped along with covering letter. Bidder has to upload scanned copy/ proof of the FDR along with bid and has to ensure delivery of hardcopy to the

Buyer within 5 days of Bid End date/ Bid Opening date

3. **Forms of EMD and PBG**

   Successful Bidder can submit the Performance Security in the form of Account Payee Demand Draft also (besides PBG which is allowed as per GeM GTC). DD should be made in favour of

   Account Officer, DHS, Sri Vijaya Puram
   payable at
   State Bank of India, Sri Vijaya Puram
   . After award of contract, Successful Bidder can upload scanned copy of the DD in place of PBG and has to ensure delivery of hard copy to the original DD to the Buyer within 15 days of award of contract.

4. **Forms of EMD and PBG**

   Successful Bidder can submit the Performance Security in the form of Fixed Deposit Receipt also (besides PBG which is allowed as per GeM GTC). FDR should be made out or pledged in the name of

   Account Officer, DHS, Sri Vijaya Puram
   A/C (Name of the Seller). The bank should certify on it that the deposit can be withdrawn only on the demand or with the sanction of the pledgee. For release of Security Deposit, the FDR will be released in favour of bidder by the Buyer after making endorsement on the back of the FDR duly signed and stamped along with covering letter. Successful Bidder has to upload scanned copy of the FDR document in place of PBG and has to ensure delivery of hard copy of Original FDR to the Buyer within 15 days of award of contract.

5. **Scope of Supply**

   Scope of supply (Bid price to include all cost components) : Only supply of Goods

6. **Purchase Preference (Centre)**

   Purchase preference to Micro and Small Enterprises (MSEs): Purchase preference will be given to MSEs as defined in Public Procurement Policy for Micro and Small Enterprises (MSEs) Order, 2012 dated 23.03.2012 issued by Ministry of Micro, Small and Medium Enterprises and its subsequent Orders/Notifications issued by concerned Ministry. If the bidder wants to avail the Purchase preference, the bidder must be the manufacturer of the offered product in case of bid for supply of goods. Traders are excluded from the purview of Public Procurement Policy for Micro and Small Enterprises. In respect of bid for Services, the bidder must be the Service provider of the offered Service. Relevant documentary evidence in this regard shall be uploaded along with the bid in respect of the offered product or service. If L-1 is not an MSE and MSE Seller (s) has/have quoted price within L-1+ 15% of margin of purchase preference /price band defined in relevant policy, such Seller shall be given opportunity to match L-1 price and contract will be awarded for percentage of 100% of total value.

7. **Certificates**

   Bidder's offer is liable to be rejected if they don't upload any of the certificates / documents sought in the Bid document, ATC and Corrigendum if any.

8. **Certificates**

   The bidder is required to upload, along with the bid, all relevant certificates such as BIS licence, type test certificate, approval certificates and other certificates as prescribed in the Product Specification given in the bid document.

9. **Buyer Added Bid Specific ATC**

   Buyer Added text based ATC clauses

   1.Copy of Valid Drug License for manufacturing / import of the product issued by the competent authority defined under Drugs & Cosmetic Act, 1940 and Medical Devices Rules, 2017 as amended till date.

2. In case of reseller, copy of the valid drug license for sale or distribution of the reseller may also be uploaded.

3. Copy of Valid Product Permission Certificate and GMP Certificate.

4. OEM Authorization certificate shall be provided.

5. Bidder and Manufacturer shall submit a valid non-conviction certificate issued by the Concerned Drug Licensing authority to the buyer at the time of bid submission. The certificate must have been issued within 12 months from the date of opening of technical bid.

6. The successful bidder shall ensure that Primary, Secondary & Tertiary packing is marked and sealed with " DHS SUPPLY NOT FOR SALE"

7.PAN Card & GST Registration of the bidder shall be provided with the technical bid.

.

10. **Turnover**

    Bidder Turn Over Criteria: The minimum average annual financial turnover of the bidder during the last three years, ending on 31st March of the previous financial year, should be as indicated in the bid document. Documentary evidence in the form of certified Audited Balance Sheets of relevant periods or a certificate from the Chartered Accountant / Cost Accountant indicating the turnover details for the relevant period shall be uploaded with the bid. In case the date of constitution / incorporation of the bidder is less than 3 year old, the average turnover in respect of the completed financial years after the date of constitution shall be taken into account for this criteria.

11. **Turnover**

    OEM Turn Over Criteria: The minimum average annual financial turnover of the OEM of the offered product during the last three years, ending on 31st March of the previous financial year, should be as indicated in the bid document. Documentary evidence in the form of certified Audited Balance Sheets of relevant periods or a certificate from the Chartered Accountant / Cost Accountant indicating the turnover details for the relevant period shall be uploaded with the bid. In case the date of constitution / incorporation of the OEM is less than 3 year old, the average turnover in respect of the completed financial years after the date of constitution shall be taken into account for this criteria. In case of bunch bids, the OEM of CATEGORY RELATED TO primary product having highest bid value should meet this criterion.

अस्वीकरण/Disclaimer

The Additional Terms and Conditions (ATC) have been incorporated by the Buyer after approval of their Competent Authority. The Buyer ,is solely responsible for the impact of these clauses on the bidding process, its outcome, and consequences thereof including any restriction arising in the bidding process due to these ATCs and including the modification of technical specifications and / or terms and conditions governing the bid.All representations / grievances pertaining to the ATC clauses shall be raised with the buyer organization directly and not with GeM.If any of the clause(s) is/are incorporated by the Buyer regarding the following, the bid & resultant contract shall be treated as null & void. Further, GeM reserves the right, at its sole discretion, to cancel the bid forthwith, without issuance of any prior notice or intimation :-

1. Publishing Custom / BOQ bids for items for which regular GeM categories are available (unless such Custom / BOQ item is bunched with the major regular product Category Item).
2. Mandating procurement of / from specific Brand / Make / Model / Manufacturer / Dealer except in case of Single Bid / Proprietary Article Certificate (PAC) Buying.
3. Inclusion of disqualification criteria related to suspension of seller / service provider, where such suspension period has already expired.
4. Mandating submission of documents (other than EMD and signed Integrity Pact - which can be submitted

within 5 days of bid opening) in physical form as a pre-requisite to qualify bidders.

5. Publishing bids on GeM for procurement of works.
6. Procurement of Goods by creating a Service bid on GeM & vice-versa.
7. Seeking sample with bid or approval of samples during bid evaluation process. However, trial / sample, as the case may be, shall be permitted in cases where trial / sample are allowed as per approved and published procurement policy of the Buyers' controlling Ministry / Department / State / Public Sector Enterprises Headquarters. If there is any violation of trial / sample clause with regard to approved policy of the Buyers' Ministry / Department / State / Public Sector Enterprises Headquarters, then this is to be determined and redressed by the concerned Buyer Organisation only.
8. Seeking experience from specific organization / department / institute only or from foreign / export experience.
9. Creating bid for items from incorrect categories.
10. Reference of conditions published on any external site or reference to external documents/clauses.
11. Asking for any Tender fee / Bid Participation fee, as the case may be.
12. Buyer added ATC Clauses which are in contravention of clauses defined in bid detail section, including specifications, EMD Detail, ePBG Detail and MII and MSE Purchase Preference sections of the bid, unless otherwise allowed by the applicable GeM GTC.
13. Any ATC clause in contravention with GeM GTC Clause 4 (xiii) (h) will be invalid. In case of multiple L1 bidders against a service bid, the buyer shall place the Contract by selection of a bidder amongst the L-1 bidders through a Random Algorithm executed by GeM system.
14. In a category based bid, adding additional items, through buyer added, additional scope of work/ additional terms and conditions/or any other document. If buyer needs more items along with the main item, the same must be added through bunching category based items or by bunching custom catalogues or bunching a BoQ with the main category based item, the same must not be done through ATC or Scope of Work.

Further, if any seller has any objection/grievance against these additional clauses or otherwise on any aspect of this bid, they can raise their representation against the same by using the Representation window provided in the bid details field in Seller dashboard after logging in as a seller. Buyer is duty bound to reply to all such representations and would not be allowed to open bids if he fails to reply to such representations.

All GeM Sellers/Service Providers shall ensure full compliance with all applicable labour laws, including the provisions, rules, schemes and guidelines under the four Labour Codes i.e. the Code on Wages, 2019; the Industrial Relations Code, 2020; the Occupational Safety, Health and Working Conditions Code, 2020; and the Code on Social Security, 2020 as and when notified and brought into force by the Government of India.

For all provisions of the Labour Codes that are pending operationalisation through rules, schemes or notifications, the corresponding provisions of the pre-existing labour enactments (such as The Minimum Wages Act, 1948, The Payment of Wages Act, 1936, The Payment of Bonus Act, 1965, The Equal Remuneration Act, 1976, The Payment of Gratuity Act, 1972, etc. and relevant State Rules) shall continue to remain applicable.

The Seller/ Service Providers shall, therefore, be responsible for ensuring compliance under:

- **All notified and enforceable provisions of the new Labour Codes as mentioned hereinabove; and**
- **All operative provisions of the erstwhile Labour Laws until their complete substitution.**

All obligations relating to wages, social security, safety, working conditions, industrial relations etc. and any other statutory requirements shall be strictly met by the Seller/ Service Provider. Any non-compliance shall constitute a breach of the contract and shall entitle the Buyer to take appropriate action in accordance with the contract and applicable law.

This Bid is governed by the General Terms and Conditions, conditions stipulated in Bid and Service Level Agreement specific to the Service, as the case may be, as provided in the Marketplace.

However, in case of Service, if any condition specified in General Terms and Conditions is contradicted by the conditions stipulated in Service Level Agreement specific to said Service, then it will over-ride the conditions in the General Terms and Conditions.

यह बिड सामान्य शर्तों के अंतर्गत भी शासित है /This Bid is also governed by the General Terms and Conditions

जेम की सामान्य शर्तों के खंड 26 के संदर्भ में भारत के साथ भूमि सीमा साझा करने वाले देश के बिडर से खरीद पर प्रतिबंध के संबंध में भारत के साथ भूमि सीमा साझा करने वाले देश का कोई भी बिडर इस निविदा में बिड देने के लिए तभी पात्र होगा जब वह बिड देने वाला सक्षम प्राधिकारी के पास पंजीकृत हो।बिड में भाग लेते समय बिडर को इसका अनुपालन करना होगा और कोई भी गलत घोषणा किए जाने व इसका अनुपालन न करने पर अनुबंध को तत्काल समाप्त करने और कानून के अनुसार आगे की कानूनी कार्रवाई का आधार होगा।/In terms of GeM GTC clause 26 regarding Restrictions on procurement from a bidder of a country which shares a land border with India, any bidder from a country which shares a land border with India will be eligible to bid in this tender only if the bidder is registered with the Competent Authority. While participating in bid, Bidder has to undertake compliance of this and any false declaration and non-compliance of this would be a ground for immediate termination of the contract and further legal action in accordance with the laws.

---धन्यवाद/Thank You---